Resistance Training in Adults With Obesity

Acute and Chronic Effects of Two Different Types of Resistance Training on Cardiometabolic Health in Adults With Obesity

The purpose of this project is two-fold: (1) to assess if two different resistance training protocols elicit different responses in the acute phase and (2) to assess if the same two different protocols will elicit different long-term responses on muscular strength, body composition and cardiometabolic health. The project will include 30 adults with obesity (defined as BMI ≥ 30 or abdominal obesity according to the International Diabetes Federation). In the acute phase blood lactate, heart rate, enjoyment and perceived exertion will be assessed after the two resistance training protocols. In addition, the mean 24-h blood glucose concentration after exercise will be compared between the two protocols.

For the long-term effects blood markers of cardiometabolic health, blood pressure, body composition, objectively measured physical activity and physical fitness will be assessed before and after the intervention. Also, perceived health-related quality of life will be assessed before and after the intervention.

Study Overview

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Trondheim, Norway, 7491
        • Department of Circulation and Medical Imaging

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Obesity (BMI ≥ 30) or
  • Central obesity (defined according to the International Diabetes Federation).

Exclusion Criteria:

  • Unstable angina
  • recent cardiac infarction (last 4 weeks)
  • uncompensated heart failure
  • severe valvular illness
  • pulmonary disease
  • uncontrolled hypertension
  • kidney failure
  • orthopaedic/neurological limitations
  • cardiomyopathy
  • planned operations during the research period
  • participation in a parallel study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Moderate-repetition resistance training
The participants will undergo a full-body resistance training protocol with moderate repetitions (6-12), moderate load (70-85% of 1RM), and moderate rest between sets (60-90s). Training will be undertaken three times per week.
Will undertake resistance training with moderate loads, and moderate repetitions 3 times per week for 7 weeks.
EXPERIMENTAL: High-repetition resistance training
The participants will undergo a full-body resistance training protocol with high repetitions (15+), low load (<60% of 1RM), and short rest between sets (30s). Training will be undertaken three times per week.
Will undertake resistance training with low loads, and high repetitions 3 times per week for 7 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Glycated haemoglobin (HbA1c)
Time Frame: 7 weeks
7 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fasting glucose
Time Frame: 7 weeks
7 weeks
Blood lipid concentration
Time Frame: 7 weeks
7 weeks
C-reactive protein
Time Frame: 7 weeks
7 weeks
Systolic blood pressure
Time Frame: 7 weeks
7 weeks
Diastolic blood pressure
Time Frame: 7 weeks
7 weeks
Body fat
Time Frame: 7 weeks
Measured by bioelectrical impedance (InBody 770)
7 weeks
Fat-free mass
Time Frame: 7 weeks
Measured by bioelectrical impedance (InBody 770)
7 weeks
Body mass
Time Frame: 7 weeks
Measured by bioelectrical impedance (InBody 770)
7 weeks
Visceral fat area
Time Frame: 7 weeks
Measured by bioelectrical impedance (InBody 770)
7 weeks
Waist circumference
Time Frame: 7 weeks
7 weeks
VO2max (maximal aerobic capacity)
Time Frame: 7 weeks
7 weeks
Rate of force development
Time Frame: 7 weeks
Measured by Kistler force plate
7 weeks
Muscular strength (1RM)
Time Frame: 7 weeks
Leg press and bench press
7 weeks
Muscular endurance
Time Frame: 7 weeks
Maximum number of repetitions using 50% of 1-RM
7 weeks
Physical activity
Time Frame: Baseline (before intervention), 4 and 7 weeks.
Assessed at three timepoints throughout the intervention using SenseWear armband activity monitors and/or Personal Activity IntelligenceTM (using heart rate monitors and smart phone application).
Baseline (before intervention), 4 and 7 weeks.
Health-Related Quality of Life
Time Frame: 7 weeks
Using the Short-Form 36 survey and Satisfaction with Physical Function and Appearance Survey
7 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 14, 2021

Primary Completion (ACTUAL)

February 28, 2022

Study Completion (ACTUAL)

February 28, 2022

Study Registration Dates

First Submitted

September 20, 2021

First Submitted That Met QC Criteria

October 11, 2021

First Posted (ACTUAL)

October 25, 2021

Study Record Updates

Last Update Posted (ACTUAL)

May 26, 2022

Last Update Submitted That Met QC Criteria

May 25, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Overweight and Obesity

Clinical Trials on Moderate-repetition resistance training

3
Subscribe